Stemline Therapeutics (STML) Reports Q4 Loss, Tops Revenue Estimates – NasdaqBy / March 13, 2020 Stemline Therapeutics (STML) Reports Q4 Loss, Tops Revenue Estimates Nasdaq Share this:TweetReddit